Target Name: ACTG1
NCBI ID: G71
Other Name(s): Actin gamma 1, transcript variant 2 | ACTB | Cytoskeletal gamma-actin | ACTG1 variant 1 | DFNA26 | Actin, cytoplasmic 2, N-terminally processed | ACTG | DFNA20 | Rpididymis luminal protein 176 | actin gamma 1 | Actin, cytoplasmic 2 | Actin gamma 1, transcript variant 1 | Gamma actin | ACTG_HUMAN | epididymis luminal protein 176 | BRWS2 | HEL-176 | ACTG1 variant 2 | Gamma-actin | Actin gamma 1 | cytoskeletal gamma-actin | ACT

Exploring The Potential of ACTG1 as A Drug Target and Biomarker

Actin gamma 1 (ACTG1) is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell growth and differentiation, and is involved in the development and maintenance of tissues such as muscle, bones, and skin. In addition, ACTG1 is also known to play a role in the regulation of cell survival and the response to stress.

The search for new drug targets and biomarkers is an ongoing process in the field of biology, and ACTG1 is an attractive candidate for these studies due to its unique function and the potential benefits that may be derived from manipulating its activity. In this article, we will explore the potential of ACTG1 as a drug target and the implications of targeting this protein.

Drug Target Potential

The potential of ACTG1 as a drug target is based on its unique structure and the various functions that it plays in the body. One of the key factors that make ACTG1 an attractive target is its ability to interact with a variety of different molecules. This interactivity allows ACTG1 to play a role in the regulation of a wide range of cellular processes, including cell growth, differentiation, and stress response.

In addition, ACTG1 is known to play a key role in the regulation of cell survival and the response to stress. It has been shown to play a role in the regulation of cell cycle progression, and is involved in the formation of stress-induced apoptosis. This suggests that targeting ACTG1 with drugs that can inhibit its activity could have a potential therapeutic impact on a wide range of diseases.

Biomarker Potential

The potential of ACTG1 as a biomarker is based on its involvement in the regulation of various cellular processes. It is expressed in a wide range of tissues, including muscle, bone, and skin, and has been shown to play a role in the regulation of cell growth, differentiation, and stress response.

In addition, ACTG1 has been shown to play a role in the regulation of cell survival and the response to stress. It has been shown to interact with a variety of different molecules, including transcription factors, and is involved in the regulation of cellular processes such as cell cycle progression, apoptosis, and stress response.

Targeting ACTG1 with small molecules or antibodies has the potential to be a valuable tool for the study of these processes and the development of new therapeutic approaches.

Conclusion

In conclusion, ACTG1 is an attractive candidate for drug targeting due to its unique structure and the various functions that it plays in the body. The potential of ACTG1 as a drug target and biomarker is based on its ability to interact with a variety of different molecules and its involvement in the regulation of cellular processes such as cell growth, differentiation, and stress response. Further research is needed to fully understand the potential of ACTG1 as a drug target and biomarker.

Protein Name: Actin Gamma 1

Functions: Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells

More Common Targets

ACTG1P1 | ACTG1P10 | ACTG1P12 | ACTG1P17 | ACTG1P20 | ACTG1P22 | ACTG1P25 | ACTG1P4 | ACTG2 | Actin | Activating signal cointegrator 1 complex protein | Activin receptor type 2 (nonspecifed subtype) | ACTL10 | ACTL6A | ACTL6B | ACTL7A | ACTL7B | ACTL8 | ACTL9 | ACTMAP | ACTN1 | ACTN1-DT | ACTN2 | ACTN3 | ACTN4 | ACTR10 | ACTR1A | ACTR1B | ACTR2 | ACTR3 | ACTR3B | ACTR3BP2 | ACTR3BP5 | ACTR3BP6 | ACTR3C | ACTR5 | ACTR6 | ACTR8 | ACTRT1 | ACTRT2 | ACTRT3 | ACVR1 | ACVR1B | ACVR1C | ACVR2A | ACVR2B | ACVR2B-AS1 | ACVRL1 | ACY1 | ACY3 | Acyl-CoA dehydrogenase (ACAD) | Acyl-CoA Synthetase Short-Chain | ACYP1 | ACYP2 | ADA | ADA2 | ADA2A-containing complex (ATAC) | ADAD1 | ADAD2 | ADAL | ADAM10 | ADAM11 | ADAM12 | ADAM15 | ADAM17 | ADAM18 | ADAM19 | ADAM1A | ADAM1B | ADAM2 | ADAM20 | ADAM20P1 | ADAM21 | ADAM21P1 | ADAM22 | ADAM23 | ADAM28 | ADAM29 | ADAM30 | ADAM32 | ADAM33 | ADAM3A | ADAM5 | ADAM6 | ADAM7 | ADAM7-AS1 | ADAM7-AS2 | ADAM8 | ADAM9 | ADAMDEC1 | ADAMTS1 | ADAMTS10 | ADAMTS12 | ADAMTS13 | ADAMTS14 | ADAMTS15 | ADAMTS16 | ADAMTS16-DT | ADAMTS17 | ADAMTS18